PMID- 29180848
OWN - NLM
STAT- MEDLINE
DCOM- 20180726
LR  - 20220310
IS  - 1177-8881 (Electronic)
IS  - 1177-8881 (Linking)
VI  - 11
DP  - 2017
TI  - Safety and efficacy of the addition of pertuzumab to T-DM1 +/- taxane in patients 
      with HER2-positive, locally advanced or metastatic breast cancer: a pooled 
      analysis.
PG  - 3235-3244
LID - 10.2147/DDDT.S149032 [doi]
AB  - BACKGROUND: The aim of this review was to systematically evaluate the safety and 
      efficacy of the addition of pertuzumab to trastuzumab emtansine (T-DM1) +/- taxane 
      in patients with human epidermal growth factor receptor 2 (HER2)-positive, 
      locally advanced breast cancer (LABC) or metastatic breast cancer (MBC). 
      MATERIALS AND METHODS: Several databases were searched for relevant clinical 
      trials. The study characteristics, details of adverse events (AEs) and details of 
      treatment efficacy were extracted for analysis. RESULTS: Six studies with 996 
      patients were included. Common AEs of T-DM1 + pertuzumab +/- taxane included 
      fatigue, diarrhea, nausea, epistaxis, peripheral neuropathy, increased aspartate 
      transaminase (AST), increased alanine transaminase (ALT) and thrombocytopenia. 
      Major grade >/=3 AEs of T-DM1 + pertuzumab +/- taxane included thrombocytopenia, 
      neutropenia, fatigue, increased ALT, anemia and peripheral neuropathy. The 
      addition of pertuzumab to T-DM1 +/- taxane led to higher risks of diarrhea 
      (especially grade >/=3 diarrhea), rash and vomiting, and decreased risks of 
      thrombocytopenia and grade >/=3 increased AST. The relative risks of the addition 
      of pertuzumab to T-DM1 +/- taxane for objective response (1.068, 95% CI 
      0.945-1.207) and clinical benefit (1.038, 95% CI 0.974-1.106) were not 
      statistically significant. CONCLUSION: Common AEs should be carefully monitored 
      in HER2-positive LABC or MBC patients treated with T-DM1 + pertuzumab +/- taxane. 
      The addition of pertuzumab to T-DM1 +/- taxane showed noninferior, but not 
      superior, objective response rate and clinical benefit rate. However, more 
      studies are needed to further verify these findings.
FAU - Zhang, Jing
AU  - Zhang J
AD  - Cancer Center, West China Hospital, Collaborative Innovation Center for 
      Biotherapy.
AD  - Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu.
FAU - Li, Jinying
AU  - Li J
AD  - The Second Affiliated Hospital of Medical College of Qingdao University, Qingdao 
      Central Hospital, Qingdao, People's Republic of China.
FAU - Zhu, Chenjing
AU  - Zhu C
AD  - Cancer Center, West China Hospital, Collaborative Innovation Center for 
      Biotherapy.
FAU - Song, Yanlin
AU  - Song Y
AD  - Cancer Center, West China Hospital, Collaborative Innovation Center for 
      Biotherapy.
FAU - Xia, Fan
AU  - Xia F
AD  - Cancer Center, West China Hospital, Collaborative Innovation Center for 
      Biotherapy.
FAU - Ma, Xuelei
AU  - Ma X
AD  - Cancer Center, West China Hospital, Collaborative Innovation Center for 
      Biotherapy.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20171115
PL  - New Zealand
TA  - Drug Des Devel Ther
JT  - Drug design, development and therapy
JID - 101475745
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Bridged-Ring Compounds)
RN  - 0 (Taxoids)
RN  - 14083FR882 (Maytansine)
RN  - 1605-68-1 (taxane)
RN  - EC 2.7.10.1 (ERBB2 protein, human)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - K16AIQ8CTM (pertuzumab)
RN  - P188ANX8CK (Trastuzumab)
RN  - SE2KH7T06F (Ado-Trastuzumab Emtansine)
SB  - IM
MH  - Ado-Trastuzumab Emtansine
MH  - Antibodies, Monoclonal, Humanized/*adverse effects/chemistry/*pharmacology
MH  - Antineoplastic Agents/adverse effects/chemistry/*pharmacology
MH  - Breast Neoplasms/*drug therapy/metabolism/*pathology
MH  - Bridged-Ring Compounds/chemistry/*pharmacology
MH  - Female
MH  - Humans
MH  - Maytansine/*analogs & derivatives/chemistry/pharmacology
MH  - Neoplasm Metastasis/drug therapy
MH  - Receptor, ErbB-2/*metabolism
MH  - Taxoids/chemistry/*pharmacology
MH  - Trastuzumab/chemistry/*pharmacology
PMC - PMC5695268
OTO - NOTNLM
OT  - adverse events
OT  - breast cancer
OT  - efficacy
OT  - human epidermal growth factor receptor 2
OT  - pertuzumab
OT  - trastuzumab emtansine
COIS- Disclosure The authors report no conflicts of interest in this work.
EDAT- 2017/11/29 06:00
MHDA- 2018/07/27 06:00
PMCR- 2017/11/15
CRDT- 2017/11/29 06:00
PHST- 2017/11/29 06:00 [entrez]
PHST- 2017/11/29 06:00 [pubmed]
PHST- 2018/07/27 06:00 [medline]
PHST- 2017/11/15 00:00 [pmc-release]
AID - dddt-11-3235 [pii]
AID - 10.2147/DDDT.S149032 [doi]
PST - epublish
SO  - Drug Des Devel Ther. 2017 Nov 15;11:3235-3244. doi: 10.2147/DDDT.S149032. 
      eCollection 2017.